Am J Psychiatry 156:1200-1204, August 1999
© 1999 American Psychiatric Association
Change in Basal Ganglia Volume Over 2 Years in Patients With Schizophrenia: Typical Versus Atypical Neuroleptics
Patricia Westmoreland Corson, M.D.,
Peg Nopoulos, M.D.,
Del D. Miller, Pharm.D., M.D.,
Stephan Arndt, Ph.D., and
Nancy C. Andreasen, M.D., Ph.D.
OBJECTIVE: For many years, it has been assumed that medications affect brain chemistry and physiology but not structure. Recent reports suggest that neuroleptic medication changes basal ganglia volume. To explore this possibility, the authors assessed for basal ganglia volume change in individuals who had their basal ganglia structures delineated and measured on magnetic resonance scans at the beginning and end of a 2-year period and who received neuroleptic medication during this time. METHOD: The basal ganglia volumes of 23 male patients with schizophrenia spectrum disorders were measured from manual traces delineating the caudate and lenticular nucleus on magnetic resonance images at admission and 2 years later. Patients' neuroleptic exposure was calculated over the 2 years by using a dose-year formula. RESULTS: During the 2-year period, mean basal ganglia volume of patients receiving predominantly typical neuroleptics increased, while the opposite was observed for patients receiving mostly atypical neuroleptics. Correlation analysis for the entire group showed a positive relationship between the 2-year exposure to typical neuroleptic medication and change in basal ganglia volume and the reverse for exposure to atypical neuroleptics. CONCLUSIONS: In this group, basal ganglia volume increased following exposure to typical neuroleptics and decreased following exposure to atypical neuroleptics.
This article has been cited by other articles:
|
|
|
|
 
J. Janssen, A. Diaz-Caneja, S. Reig, I. Bombin, M. Mayoral, M. Parellada, M. Graell, D. Moreno, A. Zabala, V. G. Vazquez, et al.
Brain morphology and neurological soft signs in adolescents with first-episode psychosis
The British Journal of Psychiatry,
September 1, 2009;
195(3):
227 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. K. Chan, X. Di, G. M. McAlonan, and Q.-y. Gong
Brain Anatomical Abnormalities in High-Risk Individuals, First-Episode, and Chronic Schizophrenia: An Activation Likelihood Estimation Meta-analysis of Illness Progression
Schizophr Bull,
July 24, 2009;
(2009)
sbp073v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tanskanen, K. Ridler, G. K. Murray, M. Haapea, J. M. Veijola, E. Jaaskelainen, J. Miettunen, P. B. Jones, E. T. Bullmore, and M. K. Isohanni
Morphometric Brain Abnormalities in Schizophrenia in a Population-Based Sample: Relationship to Duration of Illness
Schizophr Bull,
November 17, 2008;
(2008)
sbn141v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacol. Rev.,
September 1, 2008;
60(3):
358 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. DeLisi
The Concept of Progressive Brain Change in Schizophrenia: Implications for Understanding Schizophrenia
Schizophr Bull,
March 1, 2008;
34(2):
312 - 321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Hulshoff Pol and R. S. Kahn
What Happens After the First Episode? A Review of Progressive Brain Changes in Chronically Ill Patients With Schizophrenia
Schizophr Bull,
March 1, 2008;
34(2):
354 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. MORGAN, P. DAZZAN, K. G. ORR, G. HUTCHINSON, X. CHITNIS, J. SUCKLING, D. LYTHGOE, S.-J. POLLOCK, S. ROSSELL, J. SHAPLESKE, et al.
Grey matter abnormalities in first-episode schizophrenia and affective psychosis
The British Journal of Psychiatry,
December 1, 2007;
191(51):
s111 - s116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Binkofski, K. Reetz, C. Gaser, R. Hilker, J. Hagenah, K. Hedrich, T. van Eimeren, A. Thiel, C. Buchel, P. P. Pramstaller, et al.
Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia
Neurology,
August 28, 2007;
69(9):
842 - 850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Hoptman, J. Volavka, P. Czobor, G. Gerig, M. Chakos, J. Blocher, L. L. Citrome, B. Sheitman, J.-P. Lindenmayer, J. A. Lieberman, et al.
Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder
J Neuropsychiatry Clin Neurosci,
November 1, 2006;
18(4):
509 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tamagaki, G. C. Sedvall, E. G. Jonsson, G. Okugawa, H. Hall, S. Pauli, and I. Agartz
Altered White Matter/Gray Matter Proportions in the Striatum of Patients With Schizophrenia: A Volumetric MRI Study
Am J Psychiatry,
December 1, 2005;
162(12):
2315 - 2321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kopelman, N. C. Andreasen, and P. Nopoulos
Morphology of the Anterior Cingulate Gyrus in Patients With Schizophrenia: Relationship to Typical Neuroleptic Exposure
Am J Psychiatry,
October 1, 2005;
162(10):
1872 - 1878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, G. D. Tollefson, C. Charles, R. Zipursky, T. Sharma, R. S. Kahn, R. S. E. Keefe, A. I. Green, R. E. Gur, J. McEvoy, et al.
Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
Arch Gen Psychiatry,
April 1, 2005;
62(4):
361 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, J. S. Lapointe, and W. G. Honer
Reduced Basal Ganglia Volumes After Switching to Olanzapine in Chronically Treated Patients With Schizophrenia
Am J Psychiatry,
October 1, 2004;
161(10):
1829 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Crespo-Facorro, J.-J. Kim, E. Chemerinski, V. Magnotta, N. C. Andreasen, and P. Nopoulos
Morphometry of the Superior Temporal Plane In Schizophrenia: Relationship to Clinical Correlates
J Neuropsychiatry Clin Neurosci,
August 1, 2004;
16(3):
284 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Kemether, M. S. Buchsbaum, W. Byne, E. A. Hazlett, M. Haznedar, A. M. Brickman, J. Platholi, and R. Bloom
Magnetic Resonance Imaging of Mediodorsal, Pulvinar, and Centromedian Nuclei of the Thalamus in Patients With Schizophrenia
Arch Gen Psychiatry,
October 1, 2003;
60(10):
983 - 991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Keshavan, R. D. Sanders, J. A. Sweeney, V. A. Diwadkar, G. Goldstein, J. W. Pettegrew, and N. R. Schooler
Diagnostic Specificity and Neuroanatomical Validity of Neurological Abnormalities in First-Episode Psychoses
Am J Psychiatry,
July 1, 2003;
160(7):
1298 - 1304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. V. Sullivan, M. J. Rosenbloom, K. L. Serventi, A. Deshmukh, and A. Pfefferbaum
Effects of Alcohol Dependence Comorbidity and Antipsychotic Medication on Volumes of the Thalamus and Pons in Schizophrenia
Am J Psychiatry,
June 1, 2003;
160(6):
1110 - 1116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Peterson, P. Thomas, M. J. Kane, L. Scahill, H. Zhang, R. Bronen, R. A. King, J. F. Leckman, and L. Staib
Basal Ganglia Volumes in Patients With Gilles de la Tourette Syndrome
Arch Gen Psychiatry,
April 1, 2003;
60(4):
415 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Weinberger and R. K. McClure
Neurotoxicity, Neuroplasticity, and Magnetic Resonance Imaging Morphometry: What Is Happening in the Schizophrenic Brain?
Arch Gen Psychiatry,
June 1, 2002;
59(6):
553 - 558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Hulshoff Pol, H. G. Schnack, R. C. W. Mandl, N. E. M. van Haren, H. Koning, D. L. Collins, A. C. Evans, and R. S. Kahn
Focal Gray Matter Density Changes in Schizophrenia
Arch Gen Psychiatry,
December 1, 2001;
58(12):
1118 - 1125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Shihabuddin, M. S. Buchsbaum, E. A. Hazlett, J. Silverman, A. New, A. M. Brickman, V. Mitropoulou, M. Nunn, M. B. Fleischman, C. Tang, et al.
Striatal Size and Relative Glucose Metabolic Rate in Schizotypal Personality Disorder and Schizophrenia
Arch Gen Psychiatry,
September 1, 2001;
58(9):
877 - 884.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
